Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.08 USD | -0.08% | -0.41% | -1.39% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 14.95M | Capitalization | 510M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -111M | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M | Net cash position 2025 * | 105M | EV / Sales 2025 * | 27.1 x |
P/E ratio 2024 * |
-3.98
x | P/E ratio 2025 * |
-5
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | -0.08% | ||
1 week | -0.41% | ||
Current month | +6.43% | ||
1 month | -0.17% | ||
3 months | -24.50% | ||
6 months | +49.69% | ||
Current year | -1.39% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 04-03-25 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 19-01-31 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Albert Cha
BRD | Director/Board Member | 51 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +9.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 12.08 | -0.08% | 217,954 |
24-05-09 | 12.09 | +0.25% | 128,989 |
24-05-08 | 12.06 | -1.07% | 160,775 |
24-05-07 | 12.19 | +0.41% | 131,215 |
24-05-06 | 12.14 | +0.08% | 193,069 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.39% | 510M | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- KALV Stock